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Abstract
Trabecular bone score (TBS) is a recently-developed analytical tool that performs novel grey-level 
texture measurements on lumbar spine dual X-ray absorptiometry (DXA) images, and thereby 
captures information relating to trabecular microarchitecture. In order for TBS to usefully add to 
bone mineral density (BMD) and clinical risk factors in osteoporosis risk stratification, it must be 
independently associated with fracture risk, readily obtainable, and ideally, present a risk which is 
amenable to osteoporosis treatment. This paper summarizes a review of the scientific literature 
performed by a Working Group of the European Society for Clinical and Economic Aspects of 
Osteoporosis and Osteoarthritis. Low TBS is consistently associated with an increase in both 
prevalent and incident fractures that is partly independent of both clinical risk factors and areal 
BMD (aBMD) at the lumbar spine and proximal femur. More recently, TBS has been shown to 
have predictive value for fracture independent of fracture probabilities using the FRAX® 
algorithm. Although TBS changes with osteoporosis treatment, the magnitude is less than that of 
aBMD of the spine, and it is not clear how change in TBS relates to fracture risk reduction. TBS 
(corresponding author post-publication: nch@mrc.soton.ac.uk. (corresponding author pre-publication: 
w.j.pontefract@sheffield.ac.uk). 
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may also have a role in the assessment of fracture risk in some causes of secondary osteoporosis 
(e.g. diabetes, hyperparathyroidism and glucocorticoid-induced osteoporosis). In conclusion, there 
is a role for TBS in fracture risk assessment in combination with both aBMD and FRAX.
Keywords
osteoporosis; epidemiology; trabecular bone score (TBS); fragility fracture; bone mineral density; 
FRAX
Introduction
Osteoporosis, fragility fractures and risk assessment
Measurements of bone mineral density (BMD) are a central component of any provision that 
arises from the definition of osteoporosis, agreed internationally as: a progressive systemic 
skeletal disease characterized by low bone mass and microarchitectural deterioration of bone 
tissue, with a consequent increase in bone fragility and susceptibility to fracture [1]. This 
definition captures the notion that low areal BMD (aBMD) is an important component of 
fracture risk, but that other bone abnormalities contribute to skeletal fragility. The 
conceptual description of osteoporosis thus centres both on the assessment of bone mass and 
quality, specifically bone microstructure. Until recently, there were no satisfactory clinical 
means to assess bone microstructure non-invasively, so that the operational diagnosis of 
osteoporosis is based on the measurement of aBMD. Osteoporosis is so-defined as a femoral 
neck aBMD 2·5 SD or more below the young adult female mean (T-score ≤−2·5) [2, 3]. The 
same T-score derived at other sites is widely used in clinical practice (e.g. lumbar spine, 
total hip, distal radius).
A consequence of this operational definition, which identifies the small proportion of the 
population at highest risk, is that the greater number of individuals above this threshold, 
although individually at lower risk, contribute the greater number of fractures to the total 
burden. Indeed, the majority of fragility fractures occur in patients who have an aBMD T-
score >−2.5. In other words, the detection rate for these fractures (sensitivity) is low [4], 
which is why widespread population-based screening is not generally recommended in 
women at menopause [2, 5]. Thus, factors other than bone mass influence bone strength and 
fracture risk, including microarchitectural deterioration of bone tissue, as given in the 
conceptual definition of osteoporosis. Additional skeletal and extra-skeletal factors, such as 
bone geometry, micro-damage, mineralization, bone turnover, age, and a large range of 
clinical risk factors, including family history, prior fracture and fall risk, contribute to the 
overall assessment of fracture risk [6-9]. Several of these additional factors are captured by 
FRAX®. FRAX estimates the 10-year probability of hip and major osteoporotic fracture 
based on the individual’s risk factor profile [4]. Apart from BMD, FRAX does not capture 
other skeletal determinants of bone strength that improve upon or are at least partly 
independent of aBMD [10]. Several such determinants are the subject of clinical research 
[11-18] using novel imaging techniques, such as Quantitative Computed Tomography 
(QCT) and high resolution (peripheral) QCT [19, 20], and minimally invasive approaches 
for probing bone material properties, notably microindentation techniques [21]. Although 
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there is evidence of their predictive ability for fracture [22, 23] , none of these modalities 
appears to reliably outperform aBMD in the prediction of the various types of osteoporotic 
fractures, and their general lack of availability and validation in the clinical setting means 
that an adjunctive role alongside DXA-measured aBMD is unlikely to be feasible in most 
settings in the near future. In contrast, trabecular bone score (TBS) is a novel imaging 
technique, based on standard DXA images, and appears to constitute an index of bone 
texture that provides skeletal information additional to the standard aBMD results [24].
Trabecular bone score: definition
TBS has emerged as a novel grey-level texture measurement that uses experimental 
variograms of 2D projection images, quantifying variation in grey-level texture from one 
pixel to the adjacent pixels. TBS is not a direct measurement of bone microarchitecture but 
it is related to 3D bone characteristics such as the trabecular number, the trabecular 
separation and the connectivity density [25, 26]. An elevated TBS appears to represent 
strong, fracture-resistant microarchitecture, while a low TBS reflects weak, fracture-prone 
microarchitecture. As such, there is evidence that TBS can differentiate between two 3-
dimensional (3D) microarchitectures that exhibit the same bone density, but different 
trabecular characteristics. TBS is generally obtained by re-analysis of AP lumbar spine DXA 
images, which allows direct comparison with aBMD and application to existing datasets. 
This latter opportunity has led to a rapid rise in published research assessing its potential 
role in the assessment and management of osteoporosis.
Lumbar TBS, like aBMD, is an age dependent variable. Little change in TBS is observed 
between the ages of 30 and 45 years. Thereafter, a progressive decrease is observed with 
advancing age [27], which is more marked in women than in men. The percentage decrease 
with age is similar to that for lumbar spine aBMD, as is the short term reproducibility [25].
This paper reports the findings of a European Society for Clinical and Economic Aspects of 
Osteoporosis and Osteoarthritis (ESCEO) Working Group, which first convened in 
September 2014 with the aim of comprehensively assessing the evidence supporting the use 
of TBS in clinical practice. More specifically, this report reviews the potential value of TBS 
as an independent adjunct to risk assessment using DXA aBMD and/or FRAX in settings 
such as post-menopausal and secondary osteoporosis, and its potential use in assessment of 
response to treatment.
Search Strategy
A Medline search for publications with the terms trabecular bone score or TBS was 
undertaken in September 2014. Published articles in English and French were extracted. 
Papers in abstract form were not included except where the authors supplied a full copy of 
the submitted manuscript. A total of 479 papers were identified of which 67 manuscripts 
were considered relevant and the full publication reviewed. The search was subsequently 
updated in February 2015 and a total of 73 papers were reviewed.
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Does TBS predict osteoporosis-related fracture risk?
To date, eighteen studies assessing fracture risk in post-menopausal women have been 
published. Of these, eleven were cross-sectional [28-38] and seven prospective, including a 
meta-analysis [25, 39-44].
Cross-sectional studies
The eleven cross-sectional studies are summarized in Table 1. The studies all were 
published from 2009 onward to January 2015. Sample sizes ranged from 135 to 3069, with 
the majority between 150 and 300 subjects. Six of the studies exclusively involved post-
menopausal women, while one included only men over 40 years [31], and another both men 
and women over 50 years who had suffered at least one prior fracture [33]. There was 
variation in which fractures were assessed and how the fractures were ascertained. For 
example, five studies used self-report for all fractures, though vertebral fracture assessments 
(VFA) were used to identify vertebral fractures in three studies. In every study, however, 
and for every fracture type, there were significantly increased odds of prior fracture among 
those with low TBS even when adjusted for age, lumbar aBMD, body mass index, and 
clinical risk factors. Moreover, in one study which reported area (AUC) under receiver 
operating curves (ROC) as a combined measure of sensitivity and specificity, the AUC for 
TBS was greater than for aBMD of the spine (0.67 vs. 0.54, p = 0.035) but not for hip 
aBMD for subjects in the non-osteoporotic aBMD range [33]. However, in a further study 
which reported AUC values, these were similar for total hip BMD and total hip BMD with 
TBS (0.80 versus 0.81 respectively) [36].
Prospective studies
Cross-sectional studies may not accurately quantify the utility of a measure in the 
longitudinal prediction of incident fractures. However, data from prospective studies have 
supported the findings from the cross-sectional investigations. Of the six prospective single 
studies, one was conducted in France [28], one in the UK, France and Germany [40], three 
in Canada [25, 43, 54], and one in Japan [41] (Table 2). These cohorts tended to be larger 
than those in the cross-sectional studies, with the smallest with 560 subjects and the largest 
over 33,000 post-menopausal women; follow-up ranged from under 5 to over 8 years.
By far the largest published study assessing TBS to date was conducted in the Canadian 
province of Manitoba [46, 47], comprising 29,407 postmenopausal women (all over 50 
years, mean 65.4 years) living in and around the capital city of Winnipeg [25]. At five years 
of follow-up, there were 1668 incident major osteoporotic fractures, including 439 vertebral 
fractures and 293 hip fractures. Lumbar spine aBMD and TBS predicted fractures equally 
well, and the combination of both performed better than either individually. Interestingly, 
although aBMD-lumbar spine and aBMD-total hip were closely correlated (r = 0.72), 
aBMD-lumbar spine and TBS-lumbar spine were only weakly correlated (r = 0.32), with 
only 10% of the variance in one explained by variance in the other. Similarly weak to 
moderate correlations between aBMD and TBS have been reported by several others 
[48-53], and may relate to measurement of different bone properties, or measurement 
variability. When various models adjusted for age and clinical risk factors were tested for 
Harvey et al. Page 4
Bone. Author manuscript; available in PMC 2016 March 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
overall accuracy using receiver operating curves (ROC) and AUC estimates, the model 
combining aBMD-total hip and TBS-spine performed best, with AUC values for clinical 
vertebral and hip fractures of 0.73 (95%CI: 0.71, 0.75) and 0.82 (95%CI: 0.79, 0.84), 
respectively. For femoral neck, total hip and lumbar aBMD, the AUC improved significantly 
(p<0.001) with the inclusion of TBS. Fracture rate increased from highest to lowest third of 
TBS for subjects across the range of aBMD.
A smaller longitudinal study, conducted in France, was the OFELY (Osteoporose dans les 
Femmes de Lyon) study involving 560 post-menopausal women of mean age 65.3 years 
recruited in 2000 and 2001 and followed for a mean 7.8 years [39]. In this cohort there were 
112 incident fragility fractures that occurred in 92 women. Adjusted for age and prior 
fracture, TBS, lumbar spine and total hip aBMD were predictive of fracture occurrence. As 
with the Manitoba study, the AUC for a combined model of lumbar aBMD and TBS was 
better than that for either test used alone. TBS appeared to have the discriminative ability 
only in those women with normal or osteopenic aBMD but not for women in the 
osteoporotic aBMD range. For example, the incidence of fracture in osteopenic women with 
a TBS value in the lowest quartile was 25% compared to 13% in osteopenic women with 
TBS values in the remaining quartiles.
The Japanese Population-Based Osteoporosis Cohort Study (JPOS) prospectively followed 
665 Japanese women over the age of 50 years (mean age 64.1 years) for evidence of new 
morphometric vertebral fractures (VF), over approximately ten years [41]. During follow-
up, 92 new vertebral fractures were documented by vertebral fracture assessment (VFA). In 
contrast to the OFELY study, there was an increased rate of VF from highest to lowest third 
of TBS score irrespective of BMD; i.e., also in those women in the osteoporotic aBMD 
range; the combination of aBMD and TBS increased overall performance of VF risk 
estimation over either used alone.
In the Osteoporosis and Ultrasound Study (OPUS), 1007 post-menopausal women (mean 
age 65.9 years) were recruited from three European centres, one each in France, Germany 
and the UK, and followed for an average of 6.0 years [40]. Over those six years, there were 
82 incident clinical fractures and 46 incident vertebral fractures identified by radiography. 
TBS and aBMD at lumbar spine, femoral neck or total hip were similarly predictive of 
fragility fractures, but the combination of TBS and aBMD performed better than either 
measure alone, both in osteoporotic and non-osteoporotic women.
Only one longitudinal study on TBS has data for men (Table 2), with 3620 men over age 50 
years (mean age 67.6 years) in the Manitoba cohort, followed for an average of 4.5 years 
and sustaining 183 major osteoporotic fractures [54]. TBS was predictive of hip, vertebral or 
major fractures. However, predictive power remained significant only for hip fracture when 
adjusted for FRAX score, osteoporosis treatment, and aBMD. There was some evidence of 
an interaction between aBMD and TBS such that the relationship between TBS and incident 
fracture appeared stronger in those with an aBMD T-score < −2.5.
A recent meta-analysis of 14 prospective population-based cohorts comprising 17,809 men 
and women (59% women) examined fracture risk expressed as a gradient of risk (GR, the 
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increase in fracture risk/SD difference in TBS). The GR of TBS for hip fracture or other 
major osteoporotic fracture (clinical spine, distal forearm or proximal humerus fracture) 
ranged from 1.31 to 1.54 depending on age and fracture outcome with no difference between 
men and women [42].
These data support the utility of low lumbar TBS as a determinant of fracture risk, at least 
partly independent of aBMD. The consistency of the predictive value for fracture in 
international cohorts argues for its clinical use with aBMD.
Is TBS a potential adjunct to FRAX® probability?
FRAX is widely used as a fracture risk assessment tool and the question arises whether TBS 
might serve as an adjunct to FRAX risk factors in the stratification of fracture risk. For TBS 
to be considered clinically useful as a FRAX modifier, it should be at least partly 
independent of lumbar spine aBMD, femoral neck aBMD and FRAX clinical risk factors 
(CRFs). An assessment of the relationship between CRFs, aBMD and TBS was undertaken 
in the Manitoba cohort, in which 33,352 women aged 40–100 years (mean 63 years) with 
baseline DXA measurements of lumbar spine TBS and femoral neck aBMD were studied 
[43]. Over a mean of 4.7 years follow-up, 1,754 women died and 1,872 sustained one or 
more major osteoporotic fracture. Lower TBS predicted increased risk of incident fracture 
(HR/SD decrease: 1.36; 95%CI: 1.30, 1.42, p<0.001) and a 32% increase in death rate 
(HR/SD decrease: 1.32; 95%CI: 1.26, 1.39, p < 0.001). Lumbar spine TBS remained a 
significant predictor of major osteoporotic fracture (HR/SD decrease: 1.18; 95 %CI: 1.12, 
1.23) after adjustment for significant clinical risk factors and femoral neck aBMD. Low TBS 
(10th percentile) increased fracture risk 1.5 to 1.6-fold relative to high TBS (90th 
percentile), after accounting for competing mortality, across a wide range of ages and 
femoral neck T-scores.
Similar results were found in 3620 men from the Manitoba cohort at the age of 50 years or 
more (mean 67.6 years) [54]. Over a mean follow-up of 4.5 years, 183 men sustained major 
osteoporotic fractures and 91 clinical vertebral fractures. Lower lumbar spine TBS was 
observed in fracture versus non-fracture men for all fracture categories, and the AUC for 
incident fracture discrimination with TBS was significantly better than by chance (major 
osteoporotic fracture AUC = 0.59, p<0.001; hip fracture AUC = 0.67, p<0.001; clinical 
vertebral fracture AUC = 0.57, p = 0.032). After adjustment for FRAX without aBMD and 
osteoporosis treatment, TBS predicted major osteoporotic fracture and hip fracture (but not 
clinical vertebral fracture), and remained a predictor of hip fracture (but not major 
osteoporotic fracture) after further adjustment for hip or spine aBMD.
More recently, Manitoba data have been used to derive an adjustment factor to alter FRAX 
probabilities when accounting for TBS [55]. Data from 33,352 women between the ages of 
40 and 100 years in Manitoba were used, including baseline DXA measures of femoral neck 
aBMD and lumbar spine TBS. Hazard functions for risk of osteoporotic fracture without hip 
fracture, hip fracture, and death (since risk of death competes with risk of fracture) were 
used to compute the adjustment factor. Femoral neck aBMD, clinical risk factors and TBS 
all contributed independent predictive value to the models, and TBS modified the 10-year 
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probability of fracture outcomes generated from clinical risk factors and aBMD in FRAX-
like models. Thus, for example, in an 80-year old women, with a femoral neck T score of 
−2, and BMI 27kg/m2, the 10-year probability of major osteoporotic fracture was 16.5%. If 
her TBS were found to be low (10th percentile), this would increase her fracture probability 
to 18.0%; conversely if TBS were found to be high (90th percentile), her fracture probability 
would be reduced to 13.6%.
The validity of the adjustment to FRAX has been explored in a meta-analysis of 14 cohorts 
(excluding Manitoba), together incorporating 17,809 men and women (59% women) 
ranging in age from 40 to 90 years (mean age 72 years) [42]. FRAX and TBS both had 
predictive ability for both major osteoporotic fractures and hip fracture, partly independently 
of each other. The predictive ability of FRAX was expressed as the gradient of risk (GR; 
hazard ratio per 1SD change in risk variable in direction of increased risk). Overall, the GR 
of TBS for major osteoporotic fracture was 1.44 (95%CI: 1.35-1.53) when adjusted for age 
and time since baseline and was similar in men and women (p>0.10). When additionally 
adjusted for FRAX 10-year probability of major osteoporotic fracture, TBS remained a 
significant, independent predictor for fracture (GR 1.32, 95%CI: 1.24-1.41). The adjustment 
of FRAX probability for TBS resulted in a small increase in the GR (1.76, 95%CI: 1.65-1.87 
vs. 1.70, 95%CI: 1.60-1.81) suggesting that TBS would have clinical utility, for example, in 
the reclassification of those close to intervention thresholds.
Is TBS responsive to treatment?
Several relatively small studies have examined treatment-induced changes in TBS [49,50, 
53, 56-59] (Table 3). Of these, four were studies of osteoporosis treatment in 
postmenopausal women, one in both men and women with osteoporosis, and two in the 
management of breast cancer. One of these compared a specific oestrogen-receptor modifier 
(tamoxifen) and an aromatase inhibitor (exemestane) in breast cancer patients.
In Manitoba, 534 post-menopausal women treated with a bisphosphonate (86%), raloxifene 
(10%) or calcitonin (4%), and having more than 75% compliance, were compared with 
1,150 untreated women [50]. The mean duration of follow-up was 3.7 years. Women in the 
treated group were older (mean age 66.1 vs. 62.2 years), had lower scores for aBMD and 
lumbar TBS, and had a higher prevalence of prior major osteoporotic fracture (15.4 vs. 
10.4%) at baseline, consistent with indications for treatment. Over the course of follow-up, 
spine aBMD and TBS increased in treated women by 1.9% and 0.2%, respectively, whereas 
in untreated women aBMD and TBS decreased by 0.4% and 0.3% (all statistically 
significant changes versus baseline). Changes in aBMD and TBS from baseline were only 
weakly correlated (r = 0.20), consistent with the notion that the two indices represent partly 
independent measures of bone structure.
In the Swiss Horizon trial, 54 post-menopausal women treated with zoledronic acid were 
compared with 53 on placebo over 36 months of follow-up [52, 53]. The only clinically-
meaningful difference in baseline characteristics was a lower lumbar spine T-score in treated 
women (−2.9 vs. −2.1). Over three years, lumbar spine aBMD and TBS rose significantly, 
by 9.6% and 1.4%, respectively, in those on active treatment. The spine aBMD T-score also 
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rose by 1.4% in those on placebo, perhaps due to degenerative disease, whilst TBS declined 
by 0.5%. The first statistically-significant change from baseline for aBMD was recorded at 6 
months, whereas for TBS was at 24 months. Changes in the aBMD and TBS were only 
weakly correlated (r = 0.20) [52, 53].
In a two-year open-label study [59] comparing teriparatide (n = 65) and ibandronate (n = 
122), in which the only clinically-significant inter-group difference in baseline 
characteristics was a higher prevalence of past vertebral fractures in those on teriparatide 
(90.5 vs. 44.3%), patients on teriparatide had 7.6 and 4.3% increases in lumbar aBMD and 
TBS (both p < 0.001 vs. baseline), whilst only aBMD increased significantly in those on 
ibandronate (2.9% vs. 0.03%; p < 0.001 and 0.086, respectively). In this study, there was no 
significant correlation between changes in aBMD and TBS (r2 = 0.01). In this report, 
responsivity was also assessed as the proportion of patients achieving the least significant 
change in TBS and aBMD. For both treatment modalities lumbar spine BMD was more 
sensitive than TBS.
In an analysis of a small subset of treated female breast cancer patients in the Tamoxifen 
Exemestane Adjuvant Multicentre (TEAM) trial (n = 19 on exemestane, 17 on tamoxifen) 
[49], spine aBMD and TBS increased by 1.9 and 3.3% in those on tamoxifen versus a 5.3 
and 2.3% decrease in patients given exemestane. The disparate responses to the two drugs 
are consistent with prior research demonstrating decreased fracture risk in postmenopausal 
breast cancer patients treated with tamoxifen and the increased risk observed in those on 
exemestane [60-62]. Changes in TBS and aBMD were again only weakly correlated (r = 
0.25) [49].
A double-blind, randomized, placebo-controlled trial evaluated the effect of 8 cycles of 
adjuvant treatment with zoledronic acid over a 24-month period (4 mg i.v. once every 3 
months) compared to placebo on aBMD and TBS in premenopausal women with estrogen 
receptor and/or progesterone receptor positive breast cancer [57]. Treatment induced 
increases in both aBMD and TBS which were somewhat greater in percentage terms in the 
case of aBMD.
A cohort of 390 patients was analysed to evaluate the effect of different treatments 
(testosterone, risedronate, alendronate, denosumab, teriparatide) on aBMD and TBS [56]. 
After 24 months, a significant increase in TBS was observed only in the alendronate 
(+1.4%), denosumab (+2.8%) and teriparatide (+3.6%) groups, whereas aBMD increases in 
all treated groups. TBS was preserved on calcium and vitamin D, and decreased in the group 
without any treatment consistent with an epidemiological study showing that lower intakes 
of milk were associated with lower values for aBMD and TBS [63].
Longitudinal assessment of change represents a number of challenges both for bone 
densitometry and the evaluation of TBS. The precision of the measurement is critical, both 
within and between instruments [64]. However, sensitivity to measure changes is also 
affected by responsiveness, the ratio of responsiveness to precision being an indicator of 
sensitivity to measure (treatment-induced) changes [65]. At present, treatment induced 
changes in TBS have not been consistently assessed in this way. Nor has any possible 
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contribution of TBS to fracture efficacy been explored, given that the change in aBMD with 
treatment does not appear to fully explain the magnitude of fracture risk reduction [66;67].
Taken together, these intervention studies suggest that TBS tends to increase with treatments 
which increase aBMD, but that the magnitude of change of TBS is less marked than that of 
aBMD. It is currently unclear whether TBS might usefully contribute to the monitoring of 
treatment effects; and, given that DXA appears more responsive to change, this seems an 
unlikely outcome. However, these studies do indicate that TBS is potentially amenable to 
change as a result of pharmacological therapy. Whether this change is predictive of 
alterations in risk of future fracture, however, is currently not known.
Does TBS have a role in secondary osteoporosis?
Although in many cases, osteoporosis is idiopathic, there are a number of specific causes of 
bone fragility that result in “secondary osteoporosis”. Evidence is emerging that TBS might 
provide useful information with regards to bone health in several clinical contexts [68].
Clinical and subclinical hypercortisolism
Glucocorticoid induced osteoporosis (GIO) is common. Patients on long-term 
glucocorticoids fracture at a higher BMD than postmenopausal women, potentially implying 
a deleterious effect on bone structure. These effects may be more pronounced at lumbar 
spine; thus TBS may be well positioned to detect GIO-associated changes in bone structure.
In a cross-sectional study 65, women with systemic sclerosis were matched with 138 women 
with rheumatoid arthritis and 227 controls [69]. Multivariate analysis showed that a low 
TBS was independently associated with daily glucocorticoid dose. In a comparison of 34 
patients with adrenal tumour and subclinical hypercortisolism [70], 68 patients with a 
tumour but no subclinical hypercortisolism, and 70 matched controls, both aBMD and TBS 
were lower in those with subclinical hypercortisolism. In addition, baseline lumbar TBS 
predicted incident fractures over a mean 40 months of follow-up, independent of patient age, 
BMI and lumbar aBMD [70].
Type-2 Diabetes
There is evidence that patients with type-2 diabetes fracture at higher aBMD than 
postmenopausal women [71]. As such, there is a need for improved approaches to estimate 
fracture risk in such individuals. Recently, three studies have demonstrated that, although 
aBMD tends to be higher in type-2 diabetics than non-diabetics, the reverse is true of TBS. 
In the first paper, a cross-sectional case-control study by Dhaliwal et al., 57 women with 
type-2 diabetes were compared with 43 women without. TBS was lower and aBMD higher 
among diabetics (p = 0.001 and 0.01, respectively). Moreover, TBS was lower (p = 0.01) 
and aBMD no different in those diabetics with poor glycemic control compared to those 
with good glycemic control (an A1c above, versus below, 7.5%) [72]. The authors 
speculated that “abnormal architecture may help explain the paradox of increased fractures 
at higher aBMD” in these patients, although other mechanisms, such as glycosylation of 
collagen cross-links, key to the basic nano-structure of bone, have also been postulated [71]. 
Leslie et al [73] retrospectively analyzed data from 29,407 Canadian women age 50 years or 
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over, who had undergone a baseline DXA examination, comparing 2356 diagnosed diabetics 
with the remainder of the cohort. After adjustment for clinical risk factors, diabetic women 
were found to be more likely to be in the lowest third of lumbar TBS, but less likely to be in 
the lowest thirds of lumbar, femoral neck or total hip aBMD. Both TBS and measures of 
aBMD were predictive of incident fracture. Finally, in the Ansung cohort, which included 
1229 men and 1529 postmenopausal women (325 men and 370 women with type-2 diabetes) 
[74], lumbar spine TBS was lower in men and women with diabetes than those without, 
whereas lumbar spine BMD was higher in men and women with diabetes. Interestingly, TBS 
was negatively correlated with HbA1c, fasting plasma glucose and fasting insulin. Based on 
the above studies, TBS may aid fracture risk assessment in patients with type-2 diabetes.
Primary hyperparathyroidism
Several studies provide support for use of lumbar TBS in the management of asymptomatic 
primary hyperparathyroidism [75-78]. Romagnoli et al [77] noted lower TBS in 73 post-
menopausal women with primary hyperparathyroidism (29 of them having a documented 
vertebral fracture) than in 74 age-matched controls. In a study that included both cross-
sectional and longitudinal components, Eller-Vainicher et al [76] compared 92 patients with 
primary hyperparathyroidism (74 of them post-menopausal females and the remainder males 
over age 50 years) and 98 controls with other conditions, consecutively recruited from 
clinic. Again, TBS was lower in patients with primary hyperparathyroidism than in controls, 
and was statistically significantly associated with vertebral fracture, even after adjustment 
for age, gender, BMI and lumbar spine aBMD (adjusted OR = 1.4; 95%CI: 1.1-1.9). In the 
longitudinal phase of the study, 20 primary hyperparathyroidism patients who underwent a 
parathroidectomy to achieve ‘cure’ were compared at 24 months follow-up with 10 patients 
treated conservatively. In the surgery group, the mean TBS z-score increased by 1.20 (p < 
0.01), whilst TBS non-significantly declined in the ten conservatively-treated counterparts 
[76].
Osteoarthritis
One limitation of spinal aBMD assessment is that the presence of overlying calcifications 
due to degenerative change can erroneously elevate the resulting measurement. Recent 
studies have suggested that TBS may be less affected by such artefactual influences [79]. 
Both points were demonstrated in a recent study by Kolta et al. [80] in which 1254 post-
menopausal women in the European OPUS cohort, mean age 67 years, underwent TBS 
measurement at baseline and again at a mean of six years later. The severity of spinal 
osteoarthritis was graded according to Kellgren and Lawrence [81]. The investigators found 
that TBS was no different in women with, versus without, osteoarthritic changes in the spine 
at baseline, while lumbar spine aBMD measurements averaged 5.7% higher in the former 
group (p< 0.003). Over a mean six years of follow-up, TBS declined by 3.3% (p < 0.001), 
independent of the severity of spinal osteoarthritis. Conversely, though femoral neck and 
total hip aBMD also decreased over time and were not affected by osteoarthritis grade, there 
was no net decrease in lumbar aBMD, which was also associated with the grade of spinal 
arthritis [82].
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Currently-published data support a role for the TBS in the assessment of fragility fracture 
risk in patients with a variety of secondary causes of osteoporosis, including subclinical 
hypercortisolism, type-2 diabetes, and parathyroid disease. Clearly, prospective cohort 
studies will be needed to confirm any added utility of TBS in these specific situations over 
and above its general predictive ability for fracture.
Conclusions
In recent years, there has been increasing interest in the use of TBS, a surrogate of bone 
microarchitecture, for risk stratification in osteoporosis. The present assessment of the 
existing literature indicates that low lumbar spine TBS is associated with both a history of 
fracture and the incidence of new fracture. The effect is independent of aBMD and of 
sufficient magnitude to enhance risk stratification with aBMD. The effect is also partly 
independent of FRAX with likely greatest utility for those individuals who lie close to an 
intervention threshold. TBS increases with treatment for osteoporosis, but the magnitude of 
this change is smaller than that with bone mineral density; the relationship between change 
in TBS and magnitude of fracture risk reduction remains to be elucidated. There have been a 
number of smaller investigations, which have suggested that TBS may play a role in specific 
causes of increased fracture risk, such as glucocorticoid excess, hyperparathyroidism and 
type-2 diabetes.
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Table 3
Treatment related changes in lumbar TBS
First
author
Year
Published
Location Study
design Subjects
TBS
change/yr
Versus
baseline
Versus
other Rx
BMD
change/yr
Versus
baseline
Versus
other Rx
Krieg [50] 2013 Canada Case-control 534 PM 
women on 
standard OP 
Rx
1150 
untreated
0.20%
−0.30%
p < 
0.001
p < 
0.001
p < 0.001 1.90%
−0.40%
p < 0.002
p < 0.001
p < 0.001
Popp [53] 2013 Switzerland RCT 54 PM 
women on 
zoledronate
53 on 
placebo
0.50%
−0.20%
p < 
0.001
p < 
0.001
p < 0.001 3.20%
0.50%
p < 0.001
p < 0.001
p < 0.001
Senn [59] 2014 Switzerland Open-Label 65 PM 
women on 
teriparatide
122 PM 
women on 
ibandronate
2.20%
0.20%
p < 
0.001
p = 0.86
p < 0.001 3.80%
1.50%
p < 0.001
p < 0.001
p < 0.001
Kalder [49] 2014 Germany RCT substudy 17 PM 
women on 
tamoxifen
19 PM 
women on 
exemestane
1.70%
−1.20%
p < 0.06
p < 0.05
p < 0.001 1.00%
−2.70%
NS
p < 0.002
p < 0.001
Petranova [58] 2014 Bulgaria Observational 36 PM 
women on 
denosumab
no controls
1.70% p < 0.05 NA
Kalder [57] 2015 Germany RCT 34 women 
with breast 
cancer on 
zoledronate
36 women 
with breast 
cancer on 
placebo
2.41%
−0.52%
p<0.006 p=0.003 2.17%
−5.02%
p<0.001 p<0.005
Di Gregorio [56] 2015 Spain Open-Label 67 untreated
87 men and 
women on 
calcium and 
vitamin D
88 men and 
women on 
Alendronate
36 men on 
Testosterone
39 men and 
women on 
Risedronate
43 men and 
women on 
Denosumab
30 men and 
women on 
Teriparatide
−1.55%
0.65%
0.70%
0.90%
0.70%
1.40%
1.80%
p<0.05
NS
p<0.05
NS
NS
p<0.01
p<0.01
NA
NA
NA
NA
NA
NA
0.25%
0.80%
2.05%
2.20%
2.40%
4.40%
4.40%
NS
NS
p<0.001
p<0.001
p<0.001
p<0.001
p<0.001
NA
NA
NA
NA
NA
NA
PM = postmenopusal; NA = not applicable
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